Cargando…

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia

In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of cytarabine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azevedo, M.C., Velloso, E.D.R.P., Buccheri, V., Chamone, D.A.F., Dorlhiac-Llacer, P.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2014
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321225/ https://www.ncbi.nlm.nih.gov/pubmed/25517921 http://dx.doi.org/10.1590/1414-431X20144059

Ejemplares similares

Evaluation of chromosomal abnormalities by clg-FISH and association with proliferative and apoptotic indexes in multiple myeloma
por: Linardi, C.C.G., et al.
Publicado: (2012)

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
por: Godoy, C.R.T., et al.
Publicado: (2015)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study
por: Neto, Walter Kleine, et al.
Publicado: (2010)

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
por: Jaramillo, S, et al.
Publicado: (2017)

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
por: Chen, Guofeng, et al.
Publicado: (2022)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
por: Conchon, Monika, et al.
Publicado: (2009)

Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
por: Park, Young Hoon, et al.
Publicado: (2022)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis
por: Wu, Di, et al.
Publicado: (2017)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

P543: CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Nedumannil, Rithin, et al.
Publicado: (2023)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
por: Rassidakis, George Z., et al.
Publicado: (2018)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
por: Cortes, Jorge E., et al.
Publicado: (2020)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
por: Jost, Felix, et al.
Publicado: (2019)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
por: Hochhaus, A, et al.
Publicado: (2016)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
por: Hubeek, I, et al.
Publicado: (2005)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China
por: Wang, Ling, et al.
Publicado: (2016)

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
por: Hanoun, Maher, et al.
Publicado: (2022)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
por: Li, Zheng, et al.
Publicado: (2017)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples
por: Santos, M.F.M., et al.
Publicado: (2019)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oq9ebsu3vrplqsefp86rcshg0u